论文部分内容阅读
为了解已酰唑胺治疗中心性浆液性视网膜脉络膜病变的疗效，作者用乙酰唑胺治疗中心性浆液性视网膜脉络膜病变患者20例；另设对照组20例，观察治疗前后自觉症状、纠正视力、眼底改变、药物副作用，并随访6～8个月。结果：治疗组11人在1个半月内恢复，4人在2个月以上恢复。对照组2人在1月半内恢复，11人在2个月以上恢复。两组在1个月半内恢复率有显著差异（χ2＝7．55，P＜0．01）。治疗组与对照组患者的最终疗效及复发率则无显著差异。乙酰唑胺治疗期间未见严重药物副作用。认为口服乙酰口袋胺治疗中心性浆液性视网膜脉络膜病变能缩短病程，短期内改善自觉症状，恢复视力，但无法提高疗效及控制本病复发。
In order to understand the efficacy of 10% azoxystrobin in the treatment of central serous chorioretinopathy, the authors used acetazolamide in patients with central serous chorioretinopathy in 20 cases; the other 20 cases in the control group were observed before and after treatment of symptoms, visual acuity, Fundus changes, drug side effects, and follow-up of 6 to 8 months. Results: In the treatment group, 11 patients recovered in 1.5 months and 4 patients recovered in more than 2 months. Two people in the control group recovered in January and half and 11 people recovered in more than two months. There was a significant difference in recovery rate between the two groups in 1 and a half months (χ2 = 7.55, P <0.01). There was no significant difference in the final efficacy and recurrence between the treatment group and the control group. Acetazolamide no serious side effects during treatment. That oral acetylcysteine treatment of central serous chorioretinopathy can shorten the course of the short term to improve the symptoms, restore vision, but can not improve the efficacy and control of the disease recurrence.